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Chemical conjugationXTEN™ is a class of unstructured hydrophilic, biodegradable protein polymers designed to increase the half-lives
of therapeutic peptides and proteins. XTEN polymers and XTEN fusion proteins are typically expressed in
Escherichia coli and puriﬁed by conventional protein chromatography as monodisperse polypeptides of exact
length and sequence. Unstructured XTEN polypeptides have hydrodynamic volumes signiﬁcantly larger than
typical globular proteins of similar mass, thus imparting a bulking effect to the therapeutic payloads attached
to them. Since their invention, XTEN polypeptides have been utilized to extend the half-lives of a variety of
peptide- and protein-based therapeutics. Multiple clinical and preclinical studies and related drug discovery
and development efforts are in progress. This review details the most current understanding of physicochemical
properties and biological behavior of XTEN and XTENylated molecules. Additionally, the development path and
status of several advanced drug discovery and development efforts are highlighted.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Over the past 30 years the biopharmaceutical industry has devel-
oped many pharmaceuticals based on physiologically active peptides
and proteins such as hormones, enzymes, cytokines, antibodies and
antibody fragments, and growth and coagulation factors. As natural
components of physiological pathways, biological therapeutics tend to
be highly selective, efﬁcacious and safe. A number of therapeutic pep-
tides and proteins are administered as replacement therapy to patients
with clinical manifestation of deﬁciency, e.g. diabetes, hemophilia and
growth hormone deﬁciency (GHD). Biologics come with some limita-
tions, however. First, with very few exceptions, they cannot be given
orally but must be administered by injection. Second, peptides and
most proteins have characteristically short half-lives in circulation and
are often cleared from the bodywithin hours, if notminutes, thus neces-
sitating frequent injections during the course of treatment. Thus, to
facilitate the acceptance of new protein therapeutics and improve
patient compliance, signiﬁcant efforts have been directed toward
development of various half-life extension technologies.
The strategies to extend half-lives of therapeutic proteins are
diverse, with most approaches either linking the drug to bulking moie-
ties, or enabling FcRn-mediated recycling. Bulking approaches aim to. This is an open access article underslow down renal clearance by increasing the hydrodynamic volume of
the biologically active molecule. In addition, bulking moieties may
shield the molecule from proteolytic degradation and detection by the
host immune system, and decrease clearance receptor binding. Polyeth-
ylene glycol (PEG), historically the ﬁrst bulking agent commonly
employed to improve in vivo half-life of biotherapeutics, has been incor-
porated into multiple approved products (as reviewed in [1–4]). How-
ever, success in developing PEGylated pharmaceuticals has been
accompanied by rising concerns. PEG is not biodegradable, and cellular
vacuolation has been observed for PEGylated compounds in animal
studies [5–7]. Despite a general consensus that PEG itself is not immu-
nogenic, immunogenicity of PEGylated therapeutics was reported and
appeared to be dependent on payload, PEG size and chemical composi-
tion. The speciﬁcity and neutralizing properties of anti-PEG antibodies
detected in patients treated with PEGylated proteins remain controver-
sial [8–10]. Occurrence of anti-PEG antibodies in healthy population has
also been reported; and hypothesized to result from exposure to PEG
and PEG-containing compounds in cosmetics, pharmaceuticals and
processed foods [11–13]. The biological impact of anti-PEG antibody
expression in this population is unclear. Both the success and limitations
of PEG have spurred development of alternative biodegradable bulking
agents, such as natural and semi-synthetic polysaccharides, including
O- and N-linked oligosaccharides, dextran, hydroxyethyl starch (HES),
polysialic acid and hyaluronic acid [14,15], as well as unstructured
protein polymers such as homo-amino acid polymers, elastin-like
polypeptides, XTEN and PAS [14,16].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. SEC and SDS-PAGE characterization of XTEN polymers. XTEN864 (2), XTEN576 (3),
XTEN432 (4), XTEN288 (5) and XTEN144 (6) were prepared as described in [21,24].
XTEN1728 (1) was prepared by cross-linking two XTEN864 molecules. The Phenomenex
(Torrance, CA) columnperformance check standardmixture, preparedwith bovine thyro-
globulin (a), IgA (b), IgG (c), ovalbumin (d) and myoglobin (e), was used for comparison.
Panel A: analytical SEC was performed using a Yarra™ 3 μm SEC-4000, 300 × 7.8 mm col-
umn (Phenomenex). The mobile phase consisted of 50 mM sodium phosphate, 300 mM
sodium chloride, pH 6.5 buffer. Elution was performed at a ﬂow rate of 1 mL/min. The
upper chromatogram shows separation of globular proteins (column performance check
standard), and the lower chromatogram shows the separation of XTEN polymers of differ-
ent lengths. Panel B: comparison of molecular weight calibration curves for globular pro-
tein standards (open circles) with XTEN polymers of different length (ﬁlled squares).
Panel C: migration distances for SDS-PAGE molecular weight markers (open circles, MW
in kDa) compared with XTEN polymers of different length (ﬁlled squares).
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the FcRn receptor (reviewed in [14,17,18]). Two plasma proteins,
serumalbumin and IgG, have exceptionally longhalf-lives in circulation.
When taken up by cells through nonspeciﬁc endocytosis, both proteins
bind to the FcRn receptor in acidic endosomes and become protected
from intracellular degradation. The protein-receptor complexes are
recycled to the cell surface, where albumin and immunoglobulin
molecules are released back into circulation at the neutral pH of the
plasma. Several methods have been used to exploit the increased half-
life of IgG or albumin for therapeutic payloads: (1) genetic fusion of
the payload to the Fc domains of IgG or to the albumin polypeptide;
(2) chemical conjugation of the payload to the albumin, IgG or Fc
domain; (3) fusion or conjugation to mediator molecules which
physically bind to IgG or albumin. Examples of such mediators are
IgG-binding peptides, fatty acids, albumin-binding peptides, and
albumin-speciﬁc antibody fragments [14,16].
This review focuses on XTEN, a class of unstructured biodegradable
protein polymers developed by Amunix to increase the half-lives of
therapeutic peptides and proteins genetically fused or chemically con-
jugated to them. XTEN polymers were conceived as non-immunogenic
polypeptides consisting of the six hydrophilic, chemically stable amino
acids A, E, G, P, S and T. In order to create genetically and chemically sta-
ble polypeptides that lack secondary structure and that are highly
expressed in Escherichia coli, a library of non-repetitive 36 amino acid-
long segments was generated, and nearly 1500 unique segments were
screened for expression and biophysical properties. Selected segments
were iteratively ligated, and the resulting molecules were rescreened
for maximal expression, yielding a series of 864 residue-long polypep-
tides. The ﬁve most highly expressed of these polypeptides were tested
for genetic stability, solubility in aqueous media, heat stability, and
propensity to aggregate. Emerging from the selection process was the
polypeptide designated as XTEN [19]. The prototype molecule was
followed by development and characterization of multiple derivatives
based on the parental XTEN molecule, and today, the name XTEN
applies to the entire group of polypeptides. The physicochemical and
biological properties of XTEN protein polymers, their manufacturability
and speciﬁc applications are discussed below.
2. XTEN protein polymers
2.1. Physicochemical properties and analytics of XTEN protein polymers
The ﬁrst 864 amino acid residue XTEN (XTEN864) polypeptide
composed of A, G, E, P, S, and T was described in 2009 [19]. The selected
sequence formed the basis for the physicochemical properties displayed
by XTEN, including lack of a secondary structure, very high solubility
and low propensity toward aggregation. In the following years, shorter
XTEN polypeptides representing fragments of the parental 864 amino
acid-long molecule were explored [20,21]. While standard cloning
techniques theoretically could permit any number of amino acid
residues to be incorporated in the XTEN polypeptide, to aid in practical
and systematic evaluation, additional XTEN polymers were produced
and characterized at deﬁned fractional sizes, including 2/3 of 864 (576
residues), 1/2 (432 residues), 1/3 (288 residues), and 1/6 (144 resi-
dues). This section describes commonprotein analytical methods appli-
cable to XTEN protein polymers and highlights key differences between
XTEN and regular globular proteins and non-protein polymers. The an-
alytical methods we used to characterize XTEN include size-exclusion
chromatography (SEC), sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), electrospray ionizationmass spectrometry
(ESI-MS), reversed-phase high-performance liquid chromatography
(RP-HPLC), hydrophobic interaction chromatography (HIC), anion
exchange chromatography (AEX), dynamic light scattering (DLS), and
viscometry.
Size-exclusion chromatography (SEC) is a widely used technique to
characterize macromolecules such as polymers and proteins [22,23].Macromolecules are separated by SEC based on their hydrodynamic vol-
umes, which in turn correlate with calculatedmolecular weights (MW)
for globular proteins. For XTEN polypeptides lacking secondary struc-
ture, abnormally large hydrodynamic volumes were observed [19,20].
To explore this property further, XTEN polymers ranging from 144 to
1728 amino acid residues in length were mixed and analyzed using a
size-exclusion column with 500 Å pore size beads. For comparison, a
standard mixture of globular proteins was analyzed in parallel (Fig. 1,
A, B). As a group, XTEN polymers characteristically elute earlier than
Fig. 2. Characterization of XTEN polymers (XTEN144 (1), XTEN288 (2), XTEN432 (3),
XTEN576 (4), XTEN864 (5) and XTEN1728 (6)) by ESI-MS and HIC. Panel A: combined
ESI-MS spectra. Analysis was performed by desalting the sample ofﬂine, then infusing
into a calibrated QSTAR XL mass spectrometer (AB Sciex) [24]. Panel B: analytical HIC
was performed using a 4.6 × 100 mm ProPac HIC-10 column (Thermo Scientiﬁc). Mobile
phase A: 50mM sodiumphosphate, 1.5M ammonium sulfate, pH 7.0 buffer.Mobile phase
B: 50mM sodium phosphate, pH 7.0 buffer. Gradient: 10–80%mobile phase B, 20min at 1
mL/min.
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example, the 53 kDa XTEN576 eluted at essentially the same elution
time as the 670 kDa thyroglobulin, and the 79 kDa XTEN864 eluted as
the equivalent of a 1.5 MDa globular protein. Elution times for XTEN
polymers were inversely proportional to the logarithm of the MW
values. Notably, within the group, XTEN polymers deviated signiﬁcantly
less from the regression line than the globular proteins. Thus, regardless
of length, all XTEN polymers behaved as a homologous class of random
coil polymers. This property of XTEN is essential for tuning the pharma-
cokinetic properties of therapeutic payloads in a predictable manner.
Also, this property suggests that XTEN biodegradation upon administer-
ing an XTENylated drugwill not result in a sudden loss of drug function,
but rather will cause a gradual shortening of drug half-life. The relation-
ship between XTEN length and the half-life is discussed in Section 3.1.
While SEC is sensitive to the size of XTEN and thus can be used to
characterize aggregates in protein preparations, adding a fusion protein
or conjugation of peptide payload to XTEN864 showed no signiﬁcant
effect on its elution proﬁle [24].
SDS-PAGE, the most commonly used technique for protein analysis,
has been used for XTEN in applications ranging from testing XTEN
expression in E. coli to characterization of highly puriﬁed ﬁnal products.
Coomassie Blue stain, generally used to visualize proteins in an SDS-
PAGE gel, does not stainXTEN itself and can beused only for the analysis
of fusions and conjugates [19–21,25]. XTEN polymers can be visualized
on the gel with silver staining [24], though the method is not as sensi-
tive as for regular proteins consisting of all 20 natural amino acids.
The most suitable staining reagent for XTEN identiﬁed thus far is
Stains-All, a cationic carbocyanine dye used to stain highly anionic
proteins and nucleic acids [26,27]. Stains-All dye stains XTEN polymers
as dark blue bands with very high sensitivity (see Biodegradation
Section 3.2). By contrast, natural proteins typically stain yellow, red or
pink. This differential staining property of Stains-All dye is advanta-
geous in identifying XTENpolymers and their conjugates against a back-
ground of native proteins present in biologicalmatrices. XTEN polymers
migrate slower relative to natural proteins of similar molecular weight,
likely due to their weak binding of SDS caused by the absence of hydro-
phobic amino acids. The 79 kDa XTEN864, for example, migrates
similarly to a 160 kDa polypeptide marker [24]. Fig. 1, C illustrates
protein mobility as function of XTEN length. Similar to SEC analysis,
relative migration distances of individual XTEN polymers correlate
logarithmically to MW with minimal deviation.
Intact MW analysis by high-resolution mass spectrometry (MS) is
another useful tool for the chemical characterization of biotherapeutics.
Analysis of PEGylated proteins with MS methods yields broad mass
distribution spectra due to PEG polydispersity [28–31]. Several ap-
proaches for MS analysis of PEGylated proteins have been evaluated,
but challenges persist due to the heterogeneity inherited from PEG
[32]. By contrast, ESI-MS analysis of XTEN polymers yields singlemono-
disperse peaks with experimental values matching calculated MWs
[24]. This is a consequence of XTEN polymers being expressed as
DNA-encoded proteins with precisely deﬁned length and composition.
This property clearly distinguishes XTEN from polydisperse synthetic
polymers such as PEG and polysaccharides such as hydroxyethyl starch
(HES). Fig. 2, A shows a panel of representative reconstructed zero-
charge ESI mass spectra for 144–864 amino acids-long XTEN. Minor
peaks are usually observed exactly at 1/2 and 1/3 of full-length MW.
No corresponding bands have been detected by SDS-PAGE analysis of
the same protein preparations. These minor peaks represent artifacts
of Bayesian reconstruction and may be ignored. The monodispersity of
XTEN allows the full advantage of MS as an analytical method. Even
small changes to the protein composition, such as conjugation of a 4-
(N-maleimidomethyl)cyclohexanecarboxamido group [24], or loss of a
single N-terminal amino acid from the peptide fusion [25], have been
detected and identiﬁed by analysis of mass difference.
RP-HPLC is a sensitive and quantitative technique for the analysis of
small molecules and peptides, but its use for larger proteins is limited bythe typically poor solubility of globular proteins in organic solvents. Hy-
drophilic unstructured XTEN polymers of all sizes have been found to be
compatible with high concentrations of organic solvents, and therefore
with RP-HPLC methods. XTEN polymers bind to C4–C18-wide pore
(300 Å) matrices and quantitatively elute from the columns as sharp
peaks with a full-width-at-half-maximum (FWHM), which is essential-
ly the same as observed for short synthetic peptides [21,24]. Since XTEN
polymers lack UV absorbance at 280 nm, protein quantitation is per-
formed by RP-HPLC at 215–220 nm using reference standards
established by quantitation via amino acid analysis (AAA). The hydro-
philicity and monodispersity of XTEN render RP-HPLC to be a highly
sensitive analytical tool to almost any modiﬁcation in the chemical
structure of the XTENylated molecules. The method has been used to
monitor chemical conjugation reactions or detect post-translational
modiﬁcations of genetically fused or conjugated payloads [24]. When
analyzing unmodiﬁed XTEN, however, the elution proﬁles do not vary
substantially with the length of the XTEN polymer.
RP-HPLC and MS analysis can also be combined with proteolytic
degradation for detailed peptide mapping studies. These experiments
are used for structural sequence conﬁrmation and identiﬁcation of
post-translational modiﬁcations in proteins [33]. Trypsin, the most
commonly used enzyme for peptide mapping, does not cleave XTEN
polymers due to a lack of internal Lys and Arg residues. Conversely,
XTEN does not interfere with efﬁcient trypsin digestion of fused or
conjugated payloads.
HIC, which is commonly used for the characterization of large
proteins such as monoclonal antibodies (mAbs) and antibody drug
Fig. 3.DLS and viscosity characterization of XTEN polymers. Panel A: DLS volume distribu-
tion proﬁle of XTEN864 at 100mg/mL in phosphate buffer saline (PBS). Analysis was per-
formed using a Zetasizer Nano S system (Malvern Instruments, Westborough MA). Panel
B: DLS temperature trend graph comparing the thermal stability proﬁles of human serum
albumin (HSA) with XTEN864, both prepared at 2mg/mL in PBS. Panel C: intrinsic viscos-
ity vs. molecular weight plot for XTEN144, XTEN288, XTEN432, XTEN576, XTEN864 and
XTEN1728 polymers. Viscosity measurements were performed using a microVISC™ tem-
perature-controlled viscometer (RheoSense, San Ramon CA). The slope of the linewas de-
termined by simple linear regression analysis.
55V.N. Podust et al. / Journal of Controlled Release 240 (2016) 52–66conjugates (ADCs) [34], has been found to be useful for characterization
of XTEN polymers. In contrast to RP-HPLC, HIC efﬁciently separates
XTEN polypeptides based on polymer length, with shorter XTEN chains
eluting early in the salt gradient and longer ones eluting later (Fig. 2, B).
The method has been found to be suitable as an analytical tool to
monitor truncations of XTEN polymers in E. coli crude homogenates
and during early puriﬁcation steps. C-terminal truncations likely result
from premature termination of polypeptide biosynthesis. They lack a
C-terminal puriﬁcation tag and thus can be efﬁciently removed by tag-
selective chromatography. N-terminal truncations, likely occurring
from unspeciﬁc proteolysis intracellularly or in crude extracts, can be
removed by the ﬁnal AEX polishing step [24]. Highly puriﬁed full-
length XTEN polymers elute from HIC columns as symmetric peaks
(Fig. 2, B) while the presence of truncated XTEN species can be detected
as asymmetric ascending shoulders of the product peaks (data not
shown).
AEX is useful for both puriﬁcation and characterization of the an-
ionic XTEN polymers and their conjugates. Similar to HIC, analytical
AEX can also be used as a size-based method for the analysis of
different length XTEN polymers and their conjugates (data not
shown).
Aggregates of protein- and polymer-based therapeutics are known
to be signiﬁcant sources of drug immunogenicity and pose a signiﬁcant
efﬁcacy and safety risk [35]. DLS is an informative tool thatmay be used
to monitor aggregation in solutions [36]. DLS volume distribution anal-
ysis of XTEN864 polymer showed single peaks with low polydispersity
index values at concentrations tested up to 100 mg/mL (Fig. 3, A),
reﬂecting the intrinsic solubility-enhancing properties of the XTEN
polymer. Further studies performed using DLS with XTEN polymers
under various conditions suggest that XTEN polymers do not aggregate
in physiologically compatible solutions. At elevated temperatures,
which normally lead to irreversible denaturation and non-speciﬁc ag-
gregation of proteins, aggregation of XTEN is not observed. Fig. 3, B
shows a comparative analysis of human serum albumin and XTEN864
under increasing temperatures. While albumin exhibited progressive
aggregation at temperatures above 65 °C, XTEN polymer demonstrated
excellent thermal stability at temperatures as high as 90 °C.
Viscosity of a therapeutic protein solution is an important factor
affecting the administration of the parenteral drug via syringe [37]. A
solution viscosity below 50 cP is generally preferred for subcutaneous
injection of therapeutic proteins [38]. The absolute viscosity of
XTEN864 solution, concentrated to 100 mg/mL, was measured to be
26–30 cP, depending on the buffer system used. Depending on the
attached payload, it is likely that XTEN864 conjugates up to this concen-
tration are amenable for subcutaneous administration through a ﬁne
(27–31 gauge) needle.
Rheological measurements can also provide information regarding
the structural conformation of a polymer. For a series of chemically re-
lated polymers, a logarithm of intrinsic viscosity correlates linearly to
the logarithm of MW (Mark–Houwink–Kuhn–Sakurada equation;
[39]); the slope of the trace denotes the polymer's structural conforma-
tion in solution, with 0 corresponding to compact sphere, 0.5–0.8 to
random coil and 1.8 to rigid rod [39,40]. Intrinsic viscosities of different
length XTEN polymers in PBS at 25 °C were measured and a double
logarithmic plot of intrinsic viscosity vs MW prepared (Fig. 3, C). The
slope of the simple regression line suggests that XTEN polymers behave
like random coils at physiological pH [39]. Further studies with XTEN
protein polymers and conjugates are in progress to learn their rheolog-
ical properties.
Together these analytical techniques highlight the characteristics of
XTEN that make it a useful bulking agent for half-life extension of ther-
apeutic peptides and proteins. They also serve as predictive tools for the
properties of XTENylated fusion products or XTEN-conjugated payloads
to ensure that such molecules will have the desired physicochemical
and clinical characteristics, such as long half-life in circulation, high
solubility, and ease of manufacturing.2.2. Payload linking approaches
XTEN protein polymers consist of genetically encoded amino
acids and thus can be recombinantly fused to therapeutic proteins
or peptides. An obvious beneﬁt of genetic fusion constructs is the
convenience of expression, puriﬁcation and characterization of a sin-
gle molecule which includes both the therapeutic and bulking moie-
ties (Fig. 4, A). Multiple fusion combinations are possible depending
on whether the N- or C-termini of the therapeutic moieties are dis-
pensable for biological activity. XTEN polypeptides have been fused
to the C-termini of exenatide [19], glucagon (Gcg) [20], glucagon-
like peptide 2 (GLP2) analogue [25], and to the N-terminus of
Annexin A5 [41].
Fig. 4.XTENylation of biologically activemolecules. Panel A: Genetic fusion— a single polypeptidewhich includes both the therapeutic and bulkingmoieties. Panel B: Chemical conjugation—
XTEN is ﬁrst expressed and puriﬁed as an intermediate and then conjugated to biologically active payloads.
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XTENylated proteins is the ability to fuse multiple XTEN fragments to
a therapeutic protein of interest. This advantage has been used to
enhance the therapeutic capabilities of several products we have devel-
oped. In the case of human growth hormone (hGH), rapid kidney clear-
ance was minimized by fusion of a 912 amino acid residue sequence of
XTEN to the N-terminus of the therapeutic protein, while receptor-
mediated clearance was reduced by fusion of a 144 amino acid residue
sequence of XTEN to the C-terminus (discussed in greater detail in
Section 4.1.1). In the case of coagulation factor VIII, multiple XTEN
fragments were integrated into the native sequence of the therapeutic
polypeptide (discussed in greater detail in Section 4.2).
Chemical conjugation approach requires separate production of
XTEN and the therapeutic payload, selective cross-linking of compo-
nents, and puriﬁcation of the ﬁnal conjugate (Fig. 4, B). While these ad-
ditional steps may seem cumbersome, chemical conjugation has
distinct advantages over genetic fusion. Although XTEN fusion proteins
are typically easily expressed, some scouting and optimization of the
expression system and the puriﬁcation steps are required. In contrast,
manufactured XTEN polymers are produced in a standardized technol-
ogy platform in which expression has been optimized to yield high
titers, and the subsequent XTEN puriﬁcation processing is efﬁcient and
readily scalable, yielding homogeneous, highly puriﬁed bulk intermedi-
ates [21,24]. To be amenable to genetic fusion, the payload molecule
must be composed of proteinogenic L-amino acids, and the fusion
product must be produced as a linear unidirectional polypeptide. By
contrast, the chemical conjugation approach allows XTEN to be applied
to a broader spectrum of payloads including peptides containing non-
natural amino acids and post-translational modiﬁcations, peptoids, β-
peptides, nucleic acids and other therapeutically relevant small
molecules. Furthermore, conjugation allows the chemical payload to
be attached in any desired orientation.
An XTENpolypeptide consisting entirely of A, G, E, P, S and T carries a
single uniquely positioned reactive α-amino group. This group allows
conjugation of payloads containing reactive esters such as N-
hydroxysuccinimide (NHS) esters and tetra- or pentaﬂuorophenyl
(TFP, PFP) esters. Additional reactive amino groups can be introduced
by incorporation of lysine(s) into selected position(s) along the XTEN
polypeptide backbone by standard cloning techniques. Incorporationof cysteines into the XTEN polypeptide allows conjugation of
maleimide- and haloacetyl-containing payloads. Given sufﬁcient differ-
ences in the reactivity of amino- and thiol groups, efﬁcient orthogonal
conjugation of unrelated payloads can be accommodated. Additional
chemical modiﬁcations, such as periodate oxidation of N-terminal
serine [42,43] and conversion of naturally occurring reactive groups
such as amines and thiols into chemically orthogonal groups such as
azide, alkyne, aldehyde, alkoxyamine [44] have been demonstrated for
XTEN protein polymers (Table 1).
To date, a variety of bioactive peptides have been successfully
XTENylated. Despite the substantial negative charge and bulkiness of
XTEN, conjugation reactions generally proceed quickly and efﬁciently
for peptides of various sizes and charges, suggesting that the physico-
chemical characteristics of XTEN do not result in shielding of reactive
moieties on the polymer or unproductive repulsive or attractive interac-
tions between XTEN and the target peptide.
3. Biological properties of XTEN
3.1. Pharmacokinetics
A key attribute of the XTEN technology is the tunability of XTEN
polymer length to achieve targeted half-life [19]. Longer XTEN polypep-
tides have larger hydrodynamic volumes (Fig. 1, A) and are expected to
exhibit slower kidney clearance. Furthermore, SEC regression lines for
globular proteins and XTEN series diverge as MWs increase (Fig. 1, B),
indicating that larger XTEN gain more bulkiness than expected solely
from MW increase. As a result, the magnitude of in vivo half-life gain
has been observed to be more than the proportional increase in XTEN
length. As shown in Table 2, XTEN864 protein polymer, which is twice
the length of XTEN432, exhibits about 3-fold longer half-life than
XTEN432: 25 h versus 9 h in mice; 42.9 h versus 13.5 h in rats.
While the terminal half-lives of XTEN polymers seem to be very
predictable, linking a bioactive protein or peptide can substantially
alter these values. To give an example, green ﬂuorescent protein
(GFP), exenatide and GLP2 analogue (GLP-2G) were each fused to
XTEN864, yielding proteins with plasma half-lives in cynomolgus
monkeys of 73 h, 60 h and 120 h, respectively (Tables 2, 3), likely
reﬂecting payload-related clearance. However, the half-life of any
Table 1
Conjugation chemistries tested for XTEN protein polymers.
Payload functionality XTEN functionality XTEN derivatization Conjugation product
NHS, TFP, PFP active ester N-terminal α-amine, lysine Not needed Amide
Maleimide Cysteine Not needed Succinimidyl thioether
Thiol Maleimide Maleimide-NHS ester Succinimidyl thioether
Iodoacetyl Cysteine Not needed Thioether
Thiol Iodoacetyl Succinimidyl iodoacetate Thioether
Alkoxyamine Aliphatic aldehyde NaIO4 oxidation of N-terminal serine Oxime
Alkoxyamine Aromatic aldehyde 4-formyl-benzamido-TFP ester Oxime
Aldehyde Alkoxyamine Phthalimidooxy-NHS ester Oxime
Azide Alkyne Alkyne-NHS ester Triazole
Alkyne Azide Azide-NHS ester Triazole
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polymer, as was demonstrated by the GFP fusions to a range of XTEN
lengths (e.g. XTEN288 to XTEN864). The variation in half-life was
XTEN length-dependent, ranging from 8 h to 29 h in rats and 22 h
to 72 h in cynomolgus monkeys (Table 2). Half-life extension has
been observed in all XTEN-modiﬁed peptides and proteins analyzed
to date, including exenatide, GLP2-2G, Gcg, hGH, and coagulant
factors (Table 3, Section 4.2).
Half-life extension of therapeutic moieties leads to increased in vivo
exposure to thepharmaceuticals andmaintenance of plasma concentra-
tionswithin the therapeutic window. Although extended half-livesmay
be gained at the expense of decreased in vitro activity, the reduction in
many cases is compensated for by prolonged in vivo exposure, resulting
in improved efﬁcacy comparable to the unmodiﬁed payload at equimo-
lar doses. Another important feature of XTEN-modiﬁed therapeutics is
their relatively ﬂat peak-to-trough ratio following subcutaneous admin-
istration, a characteristic particularly helpful in preventing spikes in
drug plasma concentration that can lead to toxicity and other unfavor-
able side effects [19].
3.2. Biodegradation
To gauge the biodegradability of XTEN, puriﬁed XTEN864 was
incubated in rat plasma, rat kidney homogenate or PBS (Fig. 5). XTEN
polymer was found to be stable in plasma, with a degree of proteolysis
comparable to random hydrolysis in buffer. In contrast, XTEN was
rapidly and completely degraded in cell homogenate to low molecular
weight species with no stable intermediates. Similar observations
were made using GFP-XTEN fusion detected by Western blot using
anti-GFP antibody [19]. Rapid degradation of XTEN by intracellular
proteases implies that the protein polymer will not accumulate in
tissues following prolonged medication.
3.3. Biodistribution
The biodistribution of the 79 kDa XTEN864 protein polymer has
been investigated in Sprague Dawley rats. Animals were intravenouslyTable 2
Terminal plasma half-lives of XTEN protein polymers.
XTEN Species Half-life, h Bioanalytical method
XTEN864 Rat 42.9 ICP-MS [45,46]
XTEN576 Rat 22.6 ICP-MS
XTEN432 Rat 13.5 ICP-MS
XTEN864 Mouse 25.0 ICP-MS
XTEN432 Mouse 9.0 ICP-MS
XTEN288 Mouse b2.5 ICP-MS
GFP-XTEN864 Rat 29 Anti-GFP ELISA [19]
GFP-XTEN576 Rat 15 Anti-GFP ELISA
GFP-XTEN288 Rat 8 Anti-GFP ELISA
GFP-XTEN864 Monkey 73 Anti-GFP ELISA
GFP-XTEN576 Monkey 22 Anti-GFP ELISAinjected with XTEN864 labeled with a tag consisting of 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) coupled to a
lanthanide ion. At predetermined time points, biological samples were
collected and analyzed by inductively coupled plasma-mass spectrome-
try (ICP-MS) [45,46]. By day 14 (~8 half-lives) XTEN864 was cleared
from circulation and the combined amount of XTEN detected in all
organs totaled less than 2% of the total initial injected dose (ID). The
residual distribution of XTEN remaining in individual organs is shown
in Fig. 6, A. Accumulation in brain tissue was particularly low, being
below the limit of detection at b0.002% ID per g tissue. XTEN864 was
eliminated primarily via the kidney. Quantitation of metal in urine
accounted for 7.67% ± 1.2% ID within the 48 to 72 h collection time
frame. Feces accounted for only 1.35% ± 0.12% ID in the same time
frame. The sum of XTEN amounts excreted in urine and feces correlated
with the amount of XTEN removed from the plasma (Δmplasma), 11.4 ±
1.67% ID, during the same time (Fig. 6, B).
Biodistribution proﬁles of the 79 kDa XTEN864 and 26 kDa XTEN288
polymers were also investigated in SwissWebster mice. Both XTEN864
and XTEN288were labeled, eachwith a unique lanthanidemetal via the
DOTA chelator. Labeled XTEN was injected intravenously into mice as a
mixture. Plasma samples were collected at predetermined time points
from pre-dose to 36 h; organs were harvested at 8 h and 36 h. All sam-
ples were analyzed by ICP-MS. XTEN288, with a short half-life of less
than 2.5 h (Table 2), was rapidly cleared from both plasma and the
vital organs that were examined. XTEN864 was detected in the plasma
at high concentrations at both time points due to its much longer half-
life of 25 h (Table 2). While XTEN864 was able to penetrate all organs
except brain via the vasculature, accumulation in organ tissue was not
observed. Organ concentrations were consistent with blood concentra-
tion, likely due to plasma perfusion to the organs. These data demon-
strate that XTEN polymers accessed most tissues via the bloodstream,
but did not accumulate and were cleared from tissues when plasma
levels of XTEN decreased (Fig. 7).
This non-accumulating biodistribution proﬁle of XTEN in healthy
tissue together with its rapid biodegradability by intracellular proteases
suggests that XTEN may be a safer alternative to PEG for half-life
extension of pharmaceuticals.
3.4. Immunogenicity
BLAST analysis of established XTEN sequences shows that XTEN864
does not possess signiﬁcant homology to naturally occurring human
proteins. A scan for T cell epitopes using the ProPred MHC class II bind-
ing peptide predictor [59] against the most prevalent HLA DR alleles
revealed a complete lack of T cell epitopes (P1 anchors) within XTEN
(data not shown). Attempts to generate an anti-XTEN antibody for
bioanalytical purposes have proved to be extremely challenging. After
much effort, only a single stable low afﬁnity anti-XTEN antibody was
obtained. This was achieved by hyper-immunizing mice with
exenatide-XTEN protein in the presence of complete Freund's adjuvant.
The resultant anti-XTEN antibody was characterized to be speciﬁc for
XTEN and not for exenatide.
Table 3
Fold improvement in half-lives of XTEN-modiﬁed therapeutics.
Payload Species t1/2 of payload, h XTEN length t1/2 of XTENylated payload, h t1/2 of XTENylated payload/t1/2 of payload
Exenatide Human 2.4 [47] 864 124 [48] 52
Exenatide Mouse 0.17 [49] 864 12 [19] 71
Exenatide Rat 0.49 [49] 864 32 [19] 65
Exenatide Monkey 0.48 [50] 864 60 [19] 125
Exenatide Dog ND 864 72.8a ND
GLP2-2G Human 1.6–2.2 [51] 864 Predicted 240 [25] 109 to 150
GLP2-2G Mouse 0.37–0.58 [51] 864 34 [25] 59 to 92
GLP2-2G Rat 0.41–0.67 [51] 864 38 [25] 57 to 93
GLP2-2G Monkey 1.4 to 1.9 [51] 864 120 [25] 63 to 86
hGH Human 2–3 [52,53] 912 + 144 131 [54] 44 to 66
hGH Rat 0.53 [55] 912 + 144 15 6 [56] 28
hGH Rat 0.53 [55] 912 6.8 6 [56] 13
hGH Monkey 2 to 3 [57] 912 + 144 110 6 [56] 37 to 55
hGH Monkey 2 to 3 [57] 912 48.6 6 [56] 16 to 24
Glucagon Monkey ND 288 9 [20] ND
Glucagon Monkey ND 144 2.7a ND
Fuzeon Rat 2.8 [58] 432 55.7 [21] 20
ND, not determined.
a Unpublished data.
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evaluated through two XTEN-modiﬁed pharmaceuticals, VRS-859
(XTENylated exenatide) and VRS-317 (XTENylated hGH). Preclinical
pharmacokinetics and toxicity of VRS-859 (discussed in greater detail
in 4.1.2) were evaluated in mice and cynomolgus monkeys. Mice were
dosed up to 50 mg/kg every other day for 29 days followed by a 2-
week recovery period; monkeys were dosed up to 35 mg/kg weekly
for 4 weeks followed by a 2-week recovery period. In both animal
species, VRS-859 was found to be well-tolerated and generally non-
immunogenic with no adverse effect observed at highest doses tested
[60]. Results from a Phase I, single-ascending dose study designed to
evaluate the safety and tolerability of VRS-859 demonstrated that
VRS-859 in up to 200 mg dose was well tolerated with no unexpected
adverse events [48].
The most advanced immunogenicity evaluation of XTEN has been
performed with VRS-317, an XTENylated hGH currently in Phase III
clinical testing in children with GHD (discussed in greater detail inFig. 5.Biodegradation of XTEN864. XTENwas added to rat plasma, rat kidney homogenate,
or PBS to aﬁnal concentration 0.3mg/mL and incubated at 37 °C, thenmixedwith two vol-
umes of cold methanol. Precipitated media proteins were removed by centrifugation. Su-
pernatants were concentrated by evaporation, redissolved in loading buffer and analyzed
by SDS-PAGE. Proteins were visualized by Stains-All dye. The full-length XTEN864 mi-
grates on the gels at the same rate as the 160 kDa calibrant.Section 4.1.1). In a preclinical repeat dosing study involving juvenile cy-
nomolgus monkeys, VRS-317 was dosed at 0.4 and 1.4 mg/kg every
28 days for 84 days with 4 animals per dose group. Clinical pathology
performed on pre-dose and various post-dose time points revealed no
signiﬁcant changes in clinical chemistry and hematology. An immuno-
genicity evaluation revealed that two monkeys in the 1.4 mg/kg dose
group developed low titer antibody to VRS-317 at day 85. The antibody
was found to be speciﬁc to hGH but not the XTEN domain; and was
attributed to the lack of homology between cynomolgus GH and
rhGH. Importantly, the pharmacokinetics and pharmacodynamics
proﬁles were not affected, suggesting that the low titer antibody
response is unlikely to have a signiﬁcant clinical effect [56]. Phase Ia
immunogenicity evaluation of VRS-317 demonstrated that 4 out of 40Fig. 6. Lack of accumulation of XTEN864 in body organs. Panel A: XTEN864 polymer was
labeled at the N-terminal α-amino group with DOTA-NHS ester (Macrocyclics, Dallas
TX), then labeled with lanthanide metal and injected intravenously into rats. At
predetermined time points, plasma, feces and urine were collected. Additionally, various
organs such as brain, spleen, heart, kidney, liver, mesenteric adipose tissue and lungs
were harvested. All samples were analyzed by ICP-MS to determine the concentration of
the lanthanide metal label [45,46]. Panel B: plasma samples were taken at 48 and 72 h
post injection and analyzed for metal content to determine Δmplasma value. Excrement
sampleswere collected between 48 and 72h post injection and analyzed formetal content
to evaluate the XTEN elimination route.
Fig. 7.Non-accumulation of XTEN288 andXTEN864 innormalmouse tissues. XTEN864 andXTEN288were labeledwith lanthanidemetal DOTA tags and injected intomice. At 8 h and 36h
time points, the animals were sacriﬁced and the organs were analyzed for levels of the lanthanide metal labels.
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response at 30 days and/or 60 days after VRS-317 dosing. Three of the
4 adult GHD patients had an antibody titer of 1:5 and one patient a
titer of 1:25. However, upon further analysis in an anti-hGH antibody
assay, antibody detected in 3 of the 4 patients was found to beFig. 8. Dual inhibition of hGH clearance by XTEN. Panel A: native hGH, cleared by 2 routes with
duces renal clearance (half-life in monkeys 49 h [56]). Panel C: VRS-317 (hGHwith XTEN at C-
110 h [56]). Binding afﬁnity was measured using an ELISA-based receptor binding assay [56].nonspeciﬁc [54]. Subsequent Phase Ib/IIa and Phase IIb extension stud-
ies in pre-pubescent children with GHD all demonstrated that VRS-317
is well-tolerated with no unexpected adverse events [61–63].Taken to-
gether, existing clinical data suggest that XTEN has low or no immuno-
genicity in humans.terminal half-life 2–3 h in monkeys [57]. Panel B: N-terminal XTEN912 fusion to hGH re-
and N-termini) reduces both renal and receptor-mediated clearance (half-life inmonkeys
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4.1. Half-life extension by genetic fusion to peptides and proteins
4.1.1. Human growth hormone
Current hGH replacement therapy for children with GHD requires
daily injections of recombinant hGH over a number of years. Maintain-
ing full treatment compliance is challenging for many young patients,
and dose omissions are found to occur frequently [64–67]. Lack of
compliancewith daily hGH therapy has been associatedwith statistical-
ly signiﬁcant diminished growth velocities [68]. Thus, a long acting hGH
product to reduce dosing frequency and improve compliance and
overall treatment outcomes would be highly desirable.
Human growthhormone is eliminated from thebodyby both kidney
ﬁltration and receptor-mediated clearance (Fig. 8), resulting in a short
half-life of the drug of 2–3 h in monkeys. VRS-317, a novel, long-
acting hGH-XTEN fusion protein under clinical development for the
treatment of GHD, was speciﬁcally designed to encompass such dual
clearance inhibition mechanism, and thereby achieving an extended
t1/2 of 15 h in rats and 110 h in monkeys [56]. Despite a measured 12-
fold reduction of in vitro activity compared to native hGH, the enhanced
in vivo exposure to target tissues and organs compensates for the loss
with VRS-317 attaining amore than a 3- and 5-fold gain in efﬁcacy com-
pared to daily hGH in hypophysectomized rats and juvenile monkeys
respectively [56].
Clinical evaluation of VRS-317 was initiated in 2012 in 50 GHD
adults. In this single ascending dose study, VRS-317 was found to be ef-
ﬁcacious, well-tolerated with no unexpected or serious adverse events.
A half-lifewas determined to be 131 h, highlightingVRS-317 as a poten-
tial monthly dose therapy [54]. This study was followed by Phase Ib/IIa
trials in treatment naïve pre-pubescent GHD childrenwith a subcutane-
ous dosing regimen of 5 mg/kg monthly, 2.5 mg/kg semi-monthly and
1.25 mg/kg weekly. Upon achieving positive efﬁcacy as determined by
annualized height velocity and safety endpoints, the Phase IIa study
was extended for an additional 6 months to a Phase IIb with 5 mg/kg
monthly, 2.5 mg/kg semi-monthly and the 1.25 mg/kg weekly arm
transitioned to a 3.5 mg/kg semi-monthly arm. The rate of adverse
events was lower in the second 6 months of the trial and safety was
comparable to daily GH treatment. Insulin-like growth factor 1 (IGF-1)
levels in the 3.5 mg/kg semi-monthly dose cohort were almost a full
standard deviation (SD) higher than the mean IGF-1 SD experienced
by the 2.5 mg/kg semi-monthly cohort. In addition, a subset of the
3.5 mg/kg semi-monthly cohort recorded an increased mean annual-
ized height gain from 7.5 cm/year in the ﬁrst 6 months to 9.3 cm/year
during the second6months of the study. Themeanheight velocitymea-
sured after 12 months of continuous VRS-317 therapy for patients who
remained on the 5 mg/kg monthly and 2.5 mg/kg semi-monthly doses
in the extension study was determined to be not signiﬁcantly different
from the mean height velocity observed in the same patients at 3, 6
and 9 months. In addition, the mean height velocity for patients com-
pleting 12 months of treatment at 2.5 mg/kg semi-monthly was 8.5
cm/year, consistent with the ﬁrst year growth rate for moderate GHD
patients receiving the highest approved dose of hGH [63]. Following
positive outcomes from the Phase I and II studies, a Phase III study has
been initiated in US, Europe and Canada, with a primary endpoint of
non-inferiority for 12 month height velocity between 3.5 mg/kg VRS-
317 dosed twice-monthly and control group receiving daily hGH dosing
[69]. A Phase 2/3 study has also commenced in Japan [70].
4.1.2. Exenatide
Type 2 diabetes (T2D) constitutes approximately 90–95% of all
diabetes cases in US, with aging, family history, obesity and physical in-
activity being the major causes [71,72]. Exenatide is a 39 amino-acid
peptidewith effects similar to glucagon-like peptide 1 (GLP-1), current-
ly marketed as Byetta for the treatment of T2D. Owing to its small size
and rapid renal clearance, Byetta has a plasma half-life of 2.4 h and isdosed twice daily. The most common reported side effects associated
with Byetta therapy are nausea, vomiting and diarrhea [47]. In 2012,
Bydureon, a slow release version of Byetta, was approved by the FDA
as the ﬁrst once-weekly GLP-1 medicine for T2D. However, Bydureon
suffers from a high incidence of injection-site nodules [73].
To extend the circulating half-life of exenatide, XTEN864 was fused
to the C-terminus of the peptide [19]. The fusion molecule is known
as exenatide-rPEG or VRS-859 [74]. VRS-859 was extensively tested in
animal models, and based on allometric scaling from pharmacokinetic
parameters determined in mice, rats, monkeys, and dogs, a half-life of
139 h was predicted in human. As is characteristic of XTEN fusion pro-
teins, VRS-859 exhibits a slow absorption phase and a relatively ﬂat
peak before reaching a linear elimination phase following subcutaneous
injection into monkeys [19]). This pharmacokinetic proﬁle has been
postulated to decrease the severity of adverse effects caused by the
sharp peak-to-trough toxicity observed for native exenatide. In a series
of pharmacodynamics studies in animal models, VRS-859 was found to
be efﬁcacious in sustaining glycemic control and imparting weight loss
[60].
A Phase I multi-center, blinded, placebo-controlled, single-
ascending dose study to evaluate the safety and tolerability of VRS-
859 in 70 T2D patients was initiated in 2010. Positive Phase I results
demonstrated that all doses administered (up to 200 mg) were well
tolerated and able to provide glycemic control in T2Dpatients. Gastroin-
testinal adverse events were generally mild and transient and resolved
in less than 24 h. Pharmacokinetics of VRS-859 was dose-linear and the
half-life was determined to be 128 h, comparable to preclinical PK
prediction by allometric scaling. The data suggest that VRS-859 has
the potential ability to maintain glycemic control for one month in
T2D patients after a single dose [48].
4.1.3. GLP2
Patients suffering from short bowel syndrome, a malabsorption
disorder caused by the surgical removal of some portion of the small
intestine due to primary causes such as cancer or Crohn's disease, can
result in the life-long dependence on parenteral nutrition,which greatly
reduces quality of life. Teduglutide, marketed as Gattex in the United
States and Revestive in Europe, is a glucagon-like peptide 2 (GLP2)
analogue indicated for the treatment of adult patients with short
bowel syndrome. Bearing a glycine substitution at position 2,
teduglutide (GLP2-2G) has increased half-life and stability as compared
to the native GLP2, prolonging half-life from 7min to 3 to 5 h in human
[75–77]. However, even with this gain in circulating half-life,
teduglutide needs to be dosed daily. A sustained exposure with a
long-acting GLP2-2G-XTEN should lead to superior efﬁcacy, less fre-
quent dosing and enhanced dosing adherence.
GLP2-2G-XTEN was produced by the genetic fusion of the GLP2-2G
peptide to an864 amino acid-longXTENat its C-terminus [25]. The plas-
ma half-life of GLP2-2G-XTEN was signiﬁcantly extended to 34 h, 38 h
and 120 h in mice, rats and monkeys respectively. Based on allometric
scaling, a half-life of 240 h in humanwas estimated, suggesting the fea-
sibility of a monthly dosing regimen in humans. When compared to
GLP2-2G peptide in a rat Crohn's disease model, GLP2-2G-XTEN was
found to require a lower molar dose and less frequent dosing to achieve
equivalent intestinotropic effects as GLP2-2G. Prophylactic administra-
tion of GLP2-2G-XTEN led to signiﬁcant increase in length, reduction
in number of trans-ulcerations and adhesions and TNF-α content of
the small intestine. These improvements in preclinical pharmacokinet-
ics, pharmacodynamics and dosing indicate that GLP2-2G-XTEN may
offer superior therapeutic beneﬁt for the treatment of short bowel syn-
drome and other gastrointestinal diseases such as Crohn's disease [25].
4.1.4. Glucagon
Hypoglycemia is themost common complication of diabetes therapy,
affecting 90% of the diabetic population [78–80], with patients who ex-
perience severe hypoglycemia having an increased mortality risk in
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Gcg, a peptide hormone capable of converting hepatic glycogen stores
into glucose for release into the bloodstream, is often administered in
such cases of acute hypoglycemic crisis. Due to its poor solubility and
stability in liquid formulation, currently marketed Gcg is supplied as
lyophilized powder requiring reconstitution [85].
While hypoglycemic events during the day can be recognized and
treated promptly, nocturnal hypoglycemia poses a more signiﬁcant
health risk, especially in juvenile type 1 diabetic patients where the
incidence of nocturnal hypoglycemic episodes is particularly high [86].
Native Gcg has an extremely short half-life of 8 to 18 min [85] and is
thus unsuitable for prophylactic use in nocturnal hypoglycemia. As the
XTEN polypeptide has the propensity to improve solubility, stability
and half-life of the attached peptide, an XTEN-modiﬁed Gcg may
prove useful for the potential prophylactic treatment of nocturnal
hypoglycemia.
An XTENylated Gcgwas generated by the recombinant fusion of 144
amino acid-long XTEN to the C-terminus of Gcg [20]. Gcg-XTEN144was
observed to have a 60-fold better solubility proﬁle than native glucagon,
allowing for liquid formulation. In a fasted beagle dog model, both Gcg-
XTEN144 and native Gcgwere found to induce a rapid increase in blood
glucose. However, only the effect of Gcg-XTEN144 was sustained for
10–12 h whereas the effect of Gcg returned to baseline by 2 h. Impor-
tantly, prophylactic administration of 0.6 nmol/kg Gcg-XTEN144 to
fasted dogs conferred strong resistance to insulin-induced hypoglyce-
mic challenge at 6 h post dose (mimicking a nocturnal hypoglycemic
episode) but not at 12 h post-dose (mimicking waking cycle) without
affecting baseline blood glucose levels [20]. These data suggest that
Gcg-XTEN144 has the potential to be an effective therapeutic in the
prevention of nocturnal hypoglycemia.
4.2. XTEN fusions to clotting factors
Hemophilia A and B are X-linked bleeding disorders caused by a
deﬁciency in either clotting factor VIII (FVIII) or factor IX (FIX) activity,
respectively. The standard treatment for hemophilia has evolved over
the years to the current preferred prophylaxis regimenswith regular in-
fusions of either plasma-derived or recombinant FVIII/FIX to replace the
missing factor, and maintain a certain amount of clotting activity in the
blood to prevent bleeds before they occur [87]. These prophylaxis regi-
mens have resulted in signiﬁcant improvements in clinical outcomes,
but have a signiﬁcant treatment burden due to the short half-lives of
the factors, such that hemophilia A patients on a prophylaxis regimen
infuse from three times per week to every other day with FVIII, and he-
mophilia B patients infuse two to three times per week with FIX [88]. In
cases where hemophilia patients develop neutralizing antibodies to
FVIII (approximately 30%) or FIX (approximately 3%), a recombinant,
activated form of factor VII (FVII) is often used (rFVIIa) to bypass the
missing factor to treat bleeds, however rFVIIa has an even shorter
half-life such that it must be infused every 2 h to control a bleed, and ef-
fective prophylaxis cannot be generally achieved [89]. While there have
been advances in the generation of longer acting FVIII and FIXmolecules
that reduce the frequency of intravenous infusions [90], there remains a
signiﬁcant unmet medical need for either further half-life extension,
and/or to enable alternate, less invasive routes of administration, such
as by subcutaneous injection. With these two goals in mind, XTEN
fusion technology was applied to all three clotting factors, initially
through C-terminal fusions.
Clotting factor IX is an approximately 55 kDa vitamin K-dependent
acid serine protease with a number of key post-translational modiﬁca-
tions such as gamma-carboxylation that require it to be generated in
mammalian cells [91]. FIX was ﬁrst generated as a C-terminal
XTEN864 fusion protein, expressed in a HEK cell line, puriﬁed by con-
ventional chromatographymethods, and pharmacokinetics determined
by assessing the FIX activity at various time points after single intrave-
nous infusion in hemophilia B mice (Fig. 9, A) [92]. The simple XTENC-terminal fusion resulted in signiﬁcant extension of half-life in com-
parison to rFIX, with a terminal half-life of 40 h, compared to an approx-
imately 15 hour terminal half-life for rFIX. Interestingly, theXTEN fusion
also increased the plasma recovery signiﬁcantly compared to rFIX (82%
v. 20%), similar to the results observed with FIX that was PEGylated on
the N-glycans of the FIX activation peptide [93]. This is consistent with
the similar mechanism of action as PEGylation, related to increased hy-
drodynamic radius and possible inhibition of clearance receptor binding
or protease cleavage, but in the case of XTEN fusion, with the added
advantages of being fully recombinant without requiring any additional
chemical modiﬁcation, and ultimately being metabolized in vivo due to
a composition of solely native amino acids. These results demonstrated
that XTEN fusions could be efﬁciently produced in mammalian cell
culture and result in signiﬁcant half-life extension of a complex biologic
compared to the unmodiﬁed protein.
Clotting factor VII is an approximately 45 kDa serine protease that
also requires posttranslational modiﬁcations such as gamma carboxyla-
tion, and therefore was generated in mammalian cells in a similar
manner to FIX. In contrast to therapeutic FIX, the therapeutic FVII is ad-
ministered as an active protease, and therefore rFVIIa variants require
an additional activation step during production. FVII was ﬁrst generated
as a C-terminal XTEN288 fusion protein, puriﬁed by conventional chro-
matographymethods, activated by incubation overnight at high protein
concentration in the presence of calcium, and the pharmacokinetics
determined by assessing the soluble tissue factor prothrombin-time
(sTF PT) activity at various time points after single intravenous infusion
in hemophilia A mice (Fig. 9, B) [94]. Here also a signiﬁcant terminal
half-life extension was observed compared to rFVIIa (8.9 h vs 1.2 h),
as well as signiﬁcant increases in recovery and area under the
pharmacokinetic curve (46 vs 9.2 h*kg/L). As with FIX, these results
demonstrate that XTEN fusion can be successfully applied to a complex
biologic and result in signiﬁcant improvements in pharmacokinetic
parameters.
Clotting factor VIII is an approximately 280 kDa protein that medi-
ates multiple protein:protein and protein:phospholipid interactions in
its function as a cofactor [95]. Deletion of a large portion of the central
B-domain (BDD, B domain deleted) reduces the size of FVIII to
170 kDa and has no effect on the functional activity of FVIII, but in-
creases expression levels in eukaryotic cells [96]. The majority of FVIII
in circulation (95–98%) is normally complexed with von Willebrand
Factor (VWF), a large glycoprotein approximately 250 kDa in size that
forms multimers up to 20 MDa, which stabilizes FVIII and protects it
from premature cleavage or clearance [95]. BDD FVIII was initially
expressed as a C-terminal XTEN864 fusion protein, puriﬁed by afﬁnity
and ion exchange chromatography, and the pharmacokinetics deter-
mined by assessing the FVIII activity at various time points after a single
intravenous infusion in hemophilia Amice (Fig. 9, C). FVIII-XTEN exhib-
ited an approximately 2 fold extension of half-life in hemophilia A mice
compared to B domain-deleted FVIII alone (Tongyao Liu, unpublished
data). While this degree of half-life extension was lower than seen
with clotting factors IX and VIIa, it is similar to that observed with a
number of other technologies applied to FVIII in preclinical studies
[90]. This is consistent with the postulate that the VWF association,
while providing stability to FVIII, also provides a half-life limitation on
FVIII, due to coupling FVIII to the VWF clearance pathways that result
in VWF having a half-life on the order of 16 h. In order to get a better as-
sessment of the half-life extension of FVIII as an XTEN fusion, these
pharmacokinetic studies were repeated in double knockout mice
(DKO) in which both the FVIII and VWF genes were deleted (Fig. 9,
D) (Tongyao Liu, unpublished data). As expected, the rFVIII control
had a much lower half-life in the absence of VWF (0.23 h in DKO vs
7.6 h in HemA), however the FVIII-XTEN demonstrated a much longer
half-life extension in these mice compared to FVIII alone (t1/2 = 7.8 h,
a 34-fold increase) with the VWF limitation removed.
In all of these studies, the initialwork focused on a simple C-terminal
XTEN fusion, however one signiﬁcant advantage of XTEN over other
Fig. 9. Pharmacokinetics of clotting factor-XTEN C-terminal fusion proteins. In order to incorporate correct posttranslational modiﬁcations, all fusion proteins were expressed in HEK cells
and puriﬁed. Activity wasmeasured after intravenous dosing. Panel A: FIX-XTEN864 compared to rFIX in FIX-deﬁcient (HemB)mice. Panel B: FVIIa-XTEN288 compared to rFVIIa in FVIII-
deﬁcient (Hem A) mice. Panels C and D: FVIII-XTEN864 compared to FVIII in HemA and FVIII/VWF double knockout (DKO) mice, respectively.
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for precise control of the placement, composition, and length of the
XTEN insertions, including multiple insertions, without chemical modi-
ﬁcation. Guided by this capability, multiple sites for XTEN insertion into
FVIII were chosen based on analyses of vertebrate sequences andmulti-
ple structures, and avoiding sites proximal to missense mutations
associatedwith hemophilia A [97]. A large number of BDD FVIII variants
with single 42 amino acid-long XTEN insertions were generated in
mammalian cells and the FVIII activity of the conditioned media
assessed as a combined measure of protein production and activity
(Fig. 10, A). Based on the analysis of these results, additional sites
were selected, and a number of BDD FVIII variants with single
XTEN144 insertions were generated and activity assessed (Fig. 10, B).
Interestingly, while the cofactor activity of FVIII requires extensive
protein–protein interactions, a large number of XTEN insertion sites
were identiﬁed that retained signiﬁcant activity (Fig. 10).
The pharmacokinetics of a subset of single XTEN144 insertions was
then assessed by activity in DKO mice following intravenous infusion
[98] (Fig. 11, A). All single XTEN144 insertions demonstrated signiﬁcant
half-life extension of the FVIII control (0.24 h), with half-lives ranging
from 2.4 to 4.5 h. Subsequent studies were then performed combining
multiple intra-domain XTEN144 insertions with B-domain and C-
terminal XTEN fusions to determine half-life in DKOmice. In general, in-
creased numbers of XTEN insertions resulted in progressively greater
half-life extension, well beyond those achieved with single C-terminal
or intra-domain insertions (Fig. 11, B). Interestingly, assessment of
single, double, or triple XTEN insertions in HemAmice all demonstrated
similar half-life extension, consistentwith the theory that VWFprovides
an upper limit on the half-life extension achievable in HemA mice.
However, these results demonstrate the versatility of the XTEN technol-
ogy in enablingmultiple insertions into a complex biologic such as FVIII
without compromising activity, and the ﬁndings have set the basis for
further work in combination with other technologies to extend the
half-life of FVIII beyond the VWF limit [99].4.3. Mono- and bi-speciﬁc conjugation
GLP2-2G peptide was the ﬁrst payload chemically conjugated to an
XTEN protein polymer [24]. Two conjugation methods were tested.
First, the α-amino group of XTEN was modiﬁed to maleimide using
sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
(sulfo-SMCC). The activated XTEN was then conjugated to the peptide
containing the C-terminal cysteine. In a second method, the peptide
carrying a 3-maleimidopropionamide group at the C-terminus was
conjugated to anXTEN polymer containing a single cysteine. In compar-
ison to recombinantly fusedGLP2-2G-XTEN [25], chemically conjugated
GLP2-2G-XTEN exhibited similar activity and plasma stability in vitro.
The in vivo half-life of the GLP2-2G-XTEN conjugate dosed subcutane-
ously in rats was 38.5 h, essentially the same as the 38 h half-life
reported for the recombinant GLP2-2G-XTEN [25]; both values are
more than 60-fold higher than the half-life in rats for the GLP2-2G
peptide itself [51].
The feasibility and beneﬁts of multivalent payload-XTEN conjuga-
tion were investigated using antiretroviral peptide T-20 (alias Fuzeon,
enfuvirtide) [21]. The 3-maleimidopropionamide-T-20 peptide was
conjugated to a series of XTEN polymers containing one or three cyste-
ines with different spacing between reactive amino acids. While the T-
20 peptide itself is known to have extremely poor solubility in aqueous
media, the puriﬁed 1x- and 3xT-20-XTEN conjugates were soluble with
no sign of aggregation. In a cell-based antiviral MAGI assay, T-20-XTEN
conjugates retained antiviral activity, which could be tuned by varying
the payload number as well as the positions of the peptides along the
XTEN polymer. The pharmacokinetics of the most active 3xT-20-
XTEN-conjugate was assayed in rats. The calculated elimination half-
life of subcutaneously injected conjugate was 55.7 ± 17.7 h, about 20
times longer than the half-life reported for T-20 peptide [21].
Bi-speciﬁc conjugation of biologically active peptides to XTEN pro-
tein polymer was demonstrated for Gcg and glucagon-like peptide-1
(GLP1) analogue [100]. N-terminal α-amines of 1x- and 3x-Thiol-
Fig. 10.Activities of FVIII-XTEN constructs. XTEN42 (Panel A) andXTEN144 (Panel B)were
inserted at positions indicated. Surface representations in the 2R7E FVIII structure indicate
residues immediately preceding sites of XTEN insertions, with green indicating approxi-
mately normal activity (≥0.1 IU/mL), yellow indicating reduced activity (b0.1 IU/mL),
and red indicating no detectable activity.
Fig. 11. Pharmacokinetics of FVIII with single or multiple intradomain XTEN insertions in
FVIII-deﬁcient (HemA) or FVIII/VWF double knockout (DKO) mice. Panel A: FVIII variants
with a single XTEN 144 insertion in the indicated domainwere assessed compared to FVIII
alone in DKO mice. Panel B: FVIII variants with the indicated total number of different
intra-domain insertions, combined with B-domain and C-terminal insertions, were
assessed in DKO and HemA mice.
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peptide was prepared with a C-terminal azido group, while the GLP1
analogue was modiﬁed with iodoacetyl group at the C-terminus. Using
copper-free click chemistry in combination with thiol/haloacetyl
chemistry, dual agonist molecules were successfully synthesized. The
activities of the conjugates were tested both in cell-based assays and
in diet-induced obese mice. Treatment of animals with the Gcg-XTEN-
GLP1 XTEN conjugates demonstrated a synergistic effect on weight
loss without compromising glycemic control [100].
5. XTEN manufacturability
The application of XTEN technology has undergone evaluation in
multiple classes of biotherapeutics including hormones, clotting factors
and peptides as described earlier [19–21,25,56]. In addition, as the
number of opportunities to utilize XTEN in chemical conjugation
applications requiring half-life extension has matured, the family of
XTEN polypeptides has expanded. Robust, scalable process platforms
have emerged as a result of the respective, manifold product develop-
ment efforts.
For both fusion products and the XTEN polypeptide stand-alone
constructs employed for chemical conjugation, commonly used E. coli
cell lines (K-12 and BL21 strains) have been adapted to serve as high-
yielding expression platforms, with titers of 3–6 g/L reported [20,24,
25]. XTENylated therapeutics have been expressed in mammalian cell
culture systems as well (see Section 4.2).
Commonly employed plasmid backbones (e.g., pBR322, pACYC)
used in the development of high-expression bacterial constructs, maybe employed to enable reliable gene insertion. The incorporation of an-
tibiotic resistance sequences (kanR or tetR) provides for efﬁcient selec-
tion and control of product expression. Additional enhancements to the
expression construct include insertion of the cer locus of the ColE1 plas-
mid, a binding site for the host encoded XerCD heterodimeric
recombinase, which serves to resolve plasmid multimers and thereby
improves plasmid stability. Conferral of enhanced plasmid stability by
the cer locus has been demonstrated to be sufﬁcient to enable
antibiotic-free fermentation.
Because XTEN protein polymers have been engineered to provide
very high solubility, the resulting fusion products aremost conveniently
expressed in the cytosol in soluble form. Depending on the genetic
elements of the strain and expression vector employed, T7/lac or phoA
promoter systems may be utilized to optimize product expression
[101]. As desired, modiﬁcations to improve strain expression perfor-
mance have been reported including selected deletions (e.g., ΔfhuA,
ΔompT, ΔphoA) conferring added phage resistance, decreased
proteolytic degradation and diminished levels of heat-shock protein
overexpression, respectively.
Puriﬁcation of soluble protein is aided by the enhanced solubility
and thermodynamic stability typically exhibited by XTEN fusion prod-
ucts. By taking advantage of these beneﬁcial attributes, robust clariﬁca-
tion from fermentation matrices involving pH and heat treatment of
product may be applied. The uniform, anionic topology and localized
charge density imparted by the XTEN peptide portion of the expressed
protein enables efﬁcient, orthogonal chromatographic processing
using conventional resins (e.g., both strong and weak cation and anion
exchangers). By taking advantage of the extended anionic charge
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consequent overall puriﬁcation yields exceeding30% are attainable [25].
Efforts to ensure enhanced stability and molecular integrity of the
target protein attainable during expression, in some instances, require
insertion of N- and C-termini modiﬁcations that include logically
inserted proteolytic sites (e.g., tobacco etch virus protease and trypsin
domains). Creating stable pre-protein expression constructs with
built-in cleavage sites allows for attachment of His-tag domains and
other stabilizing features [20,24,25] which can be used to further
expand possible downstream processing options. Subsequent applica-
tion of the appropriate enzymatic steps in the puriﬁcation processing
can be efﬁciently utilized to convert the pre-protein forms to the desired
ﬁnal product followed by quenching and removal of the unwanted
enzymatic digestion by-products.
The adaption of XTEN technology to chemical conjugation
techniques has enabled XTEN's application to the delivery of a broad
spectrum of drug payloads [21,24]. The classes of compounds amenable
for covalent linkage include a wide range of non-natural chemical moi-
eties including D-isomers and other modiﬁed amino acid containing
peptides or proteins as well as other synthetic molecules, to form
modiﬁed chemical entities not feasible with genetic fusion. Chemical
conjugation permits cross-linking of multiple copies of monospeciﬁc
molecules to XTEN polymers in any chosen orientation, as well as of
different drug classes to the same XTEN polypeptide via use of orthogo-
nal chemistries. These conjugates may be produced through the precise
positioning of chemically reactive amino acids on the XTEN backbone,
resulting in molecular entities of unique composition, structure and
activity. While typical bioactive molecules under investigation contain
1–3 linkages, up to nine chemical entities have been covalently conju-
gated to a single XTEN polypeptide, demonstrating the payload densi-
ties that can be carried by the XTEN backbone. Given XTEN's
miscibility in organic solvents (e.g., acetonitrile, dimethylformamide
and dimethyl sulfoxide) conventionally used in the generation of such
covalent linkages, efﬁcient and scalable coupling stoichiometries can
be obtained. In addition, the allowance of organic phase processing
serves to facilitate the subsequent application of ﬁnal polishing puriﬁca-
tion steps, typically involving preparative scale reverse phase liquid
chromatography.
6. Conclusions
XTENylation has been successfully tested as a viable and competitive
half-life extension technology. Its broad adoption for the development
of next-generation therapeutics will be signiﬁcantly facilitated by the
clinical success of lead candidates. Phase II clinical trials have been
completed for XTENylated hGH (VRS-317); Phase III studies have been
initiated in 2015 [69,70]. Multiple additional product candidates are in
late preclinical stages.
XTEN protein polymers combine desirable physicochemical proper-
ties of synthetic polymers with the precision of DNA-encoded protein
synthesis. The review has detailed both practical aspects of working
with this class of polymers and current knowledge about the biological
behavior of XTENylated molecules. The growing clinical experience and
expanding knowledge base continue to drive discovery, enabling the
creation of biopolymerswith evermore precision-tailored functionality.
It is foreseeable that XTEN can be used not only as a biodegradable
bulking agent, but also as an assembly platform to combine multiple
functionalities, such as targeting moieties and cytotoxic agents, into
novel therapeutics for important clinical indications.
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